Minihan, Anna

Fax: 617-732-4899
DMCC Person ID: 1955
EDRN Title: No title conferred
Specialty: None given

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

None Available.

Closed Protocols

No closed protocols.


Publication Name PubMed ID Journal
A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. 18349277 Cancer Epidemiol. Biomarkers Prev.
Blood and urine markers for ovarian cancer: a comprehensive review. 15322314 Dis. Markers
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. 15894662 Cancer Epidemiol. Biomarkers Prev.
Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. 12912935 Clin. Cancer Res.
Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. 14581349 Clin. Cancer Res.
Non-genomic biomarkers of risk in ovarian cancer. 18057519 Dis. Markers
Osteopontin as a potential diagnostic biomarker for ovarian cancer. 11926891 JAMA
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. 15161704 Clin. Cancer Res.
Pooling of case specimens to create standard serum sets for screening cancer biomarkers. 17301268 Cancer Epidemiol. Biomarkers Prev.
Promoter hypermethylation profile of ovarian epithelial neoplasms. 16061849 Clin. Cancer Res.
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. 11584061 J. Natl. Cancer Inst.
Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer. 17245808 J Bioinform Comput Biol
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. 16428483 Clin. Cancer Res.
Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. 19008269 BMJ
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). 19282241 Lancet Oncol.
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. 18061248 Gynecol. Oncol.
Urokinase-type plasminogen activator receptor: a beacon of malignancy? 18794069 Clin. Cancer Res.
Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. 18245537 Clin. Cancer Res.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.

Version 5.1.0